Clinical outcomes in patients with covid-19 and hematologic disease

Since the beginning of the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection outbreak, more vulnerable patient populations with various concomitant acute and chronic diseases have drawn particular attention from the medical and scientific community due to the numerous concerns regarding the complications, consequences, and outcomes of both the coronavirus infectious disease (COVID-19) and the underlying condition. Early reports demonstrated that patients with cancer had significantly higher risks of poor outcomes of COVID-19, including higher mortality rates, compared to the general population infected with SARS-CoV-2, whereas hematologic malignancies and lung cancer were generally associated with the highest incidence of severe events1-5.

Source: Clinical Lymphoma, Myeloma and Leukemia - April 13, 2023 Category: Hematology Authors: Olga A. Aleshina, Kristina Zakurdaeva, Anastasia N. Vasileva, Sergey K. Dubov, Vitaly S. Dubov, Vladimir I. Vorobyev, Lev S. Butaev, Alena M. Sukhareva, Lubov V. Gavrilova, Inessa Yu. Toropova, Marina O. Popova, Aleksandr A. Siniaev, Aleksandr D. Kulagin, Source Type: research